The ongoing challenge of vancomycin-resistant


Journal

Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 6 6 2020
pubmed: 6 6 2020
medline: 27 1 2021
Statut: ppublish

Résumé

Vancomycin-resistant enterococci infections are of great public health significance due to limited therapeutic options. We investigated epidemiological trends and risk factors of vancomycin resistance in enterococci isolates from patients with bloodstream infections in the EU/EEA from 2012 to 2018. Routine vancomycin susceptibility data of clinical

Identifiants

pubmed: 32498615
doi: 10.1080/22221751.2020.1769500
pmc: PMC7448851
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1180-1193

Références

J Antimicrob Chemother. 2016 Dec;71(12):3453-3458
pubmed: 27609052
Nat Rev Microbiol. 2012 Mar 16;10(4):266-78
pubmed: 22421879
Antimicrob Resist Infect Control. 2017 Jul 4;6:73
pubmed: 28680588
Antimicrob Agents Chemother. 2015 Jul;59(7):4315-7
pubmed: 25896693
Antimicrob Resist Infect Control. 2018 Jun 5;7:71
pubmed: 29992016
Medicine (Baltimore). 2016 Feb;95(8):e2831
pubmed: 26937912
Lancet Infect Dis. 2019 Jan;19(1):4-6
pubmed: 30409682
Indian J Med Microbiol. 2016 Jan-Mar;34(1):38-45
pubmed: 26776117
Microbiology (Reading). 2009 Jun;155(Pt 6):1749-1757
pubmed: 19383684
Clin Microbiol Infect. 2015 Jan;21(1):3-9
pubmed: 25636920
Zhonghua Yi Xue Za Zhi. 2018 Oct 30;98(40):3279-3287
pubmed: 30392296
J Hosp Infect. 2016 Jun;93(2):175-80
pubmed: 27112046
N Engl J Med. 2000 Mar 9;342(10):710-21
pubmed: 10706902
Emerg Infect Dis. 2005 Jun;11(6):821-8
pubmed: 15963275
Microb Drug Resist. 2017 Jun;23(4):500-506
pubmed: 27525808
J Antimicrob Chemother. 2013 May;68 Suppl 1:i31-7
pubmed: 23587776
Neoreviews. 2019 Mar;20(3):e135-e144
pubmed: 31261051
Eur J Microbiol Immunol (Bp). 2011 Sep;1(3):190-7
pubmed: 24516724
J Chemother. 2018 Sep;30(5):280-289
pubmed: 30843778
Diagn Microbiol Infect Dis. 2012 Dec;74(4):399-403
pubmed: 23099304
Adolesc Health Med Ther. 2018 Nov 15;9:177-188
pubmed: 30532606
Clin Infect Dis. 2004 Jul 15;39(2):219-26
pubmed: 15307031
Science. 2003 Nov 28;302(5650):1569-71
pubmed: 14645850
Antimicrob Resist Infect Control. 2012 Oct 08;1(1):31
pubmed: 23039285
Drug Resist Updat. 2018 Sep;40:25-39
pubmed: 30447411
Infez Med. 2017 Jun 1;25(2):116-122
pubmed: 28603229
Infect Drug Resist. 2019 Sep 02;12:2713-2725
pubmed: 31564921
Clin Infect Dis. 2019 Jul 2;69(2):259-265
pubmed: 30339217
mBio. 2013 Aug 20;4(4):
pubmed: 23963180
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S128-S134
pubmed: 30423045
J Clin Microbiol. 2006 Mar;44(3):1153-5
pubmed: 16517918
Antimicrob Resist Infect Control. 2019 Aug 28;8:147
pubmed: 31485325
Rev Soc Bras Med Trop. 2011 Mar-Apr;44(2):177-81
pubmed: 21468473
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Circulation. 2015 Oct 13;132(15):1435-86
pubmed: 26373316
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
J Med Microbiol. 2018 Aug;67(8):1069-1077
pubmed: 29923823
Chemotherapy. 1999 Mar-Apr;45(2):135-45
pubmed: 10050060
Infect Control Hosp Epidemiol. 2019 Jul;40(7):821-822
pubmed: 31088583
Infect Drug Resist. 2015 Jul 24;8:217-30
pubmed: 26244026
J Antimicrob Chemother. 2019 Dec 1;74(12):3445-3452
pubmed: 31504566
Infect Disord Drug Targets. 2020;20(6):828-833
pubmed: 31721719
Clin Microbiol Infect. 2006 Feb;12(2):163-9
pubmed: 16441455
J Glob Antimicrob Resist. 2019 Mar;16:36-47
pubmed: 30149193
Antimicrob Resist Infect Control. 2019 May 30;8:90
pubmed: 31164979
Drug Des Devel Ther. 2018 Jun 18;12:1759-1767
pubmed: 29950810
J Med Microbiol. 2017 Dec;66(12):1782-1789
pubmed: 29116037
J Am Geriatr Soc. 2002 Jul;50(7 Suppl):S226-9
pubmed: 12121517

Auteurs

Olaniyi Ayobami (O)

Unit 37: Nosocomial Infections, Surveillance of Antimicrobial Resistance and Consumption, Robert Koch Institute, Berlin, Germany.

Niklas Willrich (N)

Unit 37: Nosocomial Infections, Surveillance of Antimicrobial Resistance and Consumption, Robert Koch Institute, Berlin, Germany.

Annicka Reuss (A)

Unit 37: Nosocomial Infections, Surveillance of Antimicrobial Resistance and Consumption, Robert Koch Institute, Berlin, Germany.

Tim Eckmanns (T)

Unit 37: Nosocomial Infections, Surveillance of Antimicrobial Resistance and Consumption, Robert Koch Institute, Berlin, Germany.

Robby Markwart (R)

Unit 37: Nosocomial Infections, Surveillance of Antimicrobial Resistance and Consumption, Robert Koch Institute, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH